These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 510850)

  • 1. Potentiation of L1210 murine leukemia vaccine in vivo by levamisole.
    Kataoka T; Tsukagoshi S; Sakurai Y; Okabe M
    Gan; 1979 Aug; 70(4):515-9. PubMed ID: 510850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo potentiation of concanavalin A-bound L1210 vaccine by antimacrophage agents.
    Kataoka T; Oh-hashi F; Sakurai Y; Gomi K
    Cancer Res; 1980 Oct; 40(10):3832-8. PubMed ID: 6254642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432.
    Kataoka T; Oh-hashi F; Sakurai Y
    Cancer Res; 1979 Jul; 39(7 Pt 1):2807-10. PubMed ID: 445486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blastogenic potency of concanavalin-A-bound L1210 leukemic vaccine associated with its immunogenic activity.
    Kataoka T; Oh-hashi F; Sakurai Y
    Gan; 1979 Apr; 70(2):155-64. PubMed ID: 111995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-Mercaptopurine-induced potentiation of active immunotherapy in L1210-bearing mice treated with concanavalin A-bound leukemia cell vaccine.
    Kataoka T; Akahori Y; Sakurai Y
    Cancer Res; 1984 Feb; 44(2):519-24. PubMed ID: 6537896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoprophylactic and immunotherapeutic response by concanavalin A-bound tumor vaccine enhanced by chemotherapeutic agents eliminating possible suppressors.
    Kataoka T; Ogihara K; Sakurai Y
    Cancer Res; 1980 Oct; 40(10):3839-45. PubMed ID: 6449286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced induction of immune resistance by concanavalin A-bound L1210 vaccine and an immunopotentiator prepared from Coriolus versicolor.
    Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
    Cancer Res; 1977 Dec; 37(12):4416-9. PubMed ID: 922733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
    Kataoka T; Kobayashi H; Sakurai Y
    Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenicity and amplifier cell production by tumor vaccines enhanced by concanavalin A.
    Kataoka T; Oh-Hashi F; Sakurai Y
    Gan; 1982 Apr; 73(2):193-205. PubMed ID: 6811360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
    Kawalec M; Skórski T; Kawiak J
    Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor dependency of concanavalin A-induced potentiation of tumor cell immunogenicity.
    Kataoka T; Oh-hashi F; Akabori Y; Sakurai Y; Okabe M; Gomi K
    Gan; 1983 Jun; 74(3):412-8. PubMed ID: 6411514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemo-immunotherapy of methylchoranthrene-induced fibrosarcoma by concanavalin A-bound tumor vaccine, levamisole and mitomycin C.
    Okabe M; Morimoto M; Marumo H
    J Pharmacobiodyn; 1982 Apr; 5(4):245-51. PubMed ID: 6811721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of levamisole administration on treatment with 6-mercaptopurine riboside of mice bearing L1210 leukemia cells.
    Miura T; Nogiwa E; Kurashige S; Maekawa T
    Cancer Res; 1980 Dec; 40(12):4813-6. PubMed ID: 7438114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical and biological adjuvants capable of potentiating tumor cell vaccine.
    Chirigos MA; Stylos WA; Schultz RM; Fullen JR
    Cancer Res; 1978 Apr; 38(4):1085-91. PubMed ID: 416906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy.
    Mathé G; Florentin I; Olsson L; Bruley-Rosset M; Schulz J; Kiger N; Orbach-Arbouys S; Schwarzenberg L; Pouillart P; de Vassal F
    Cancer Treat Rep; 1978 Nov; 62(11):1613-21. PubMed ID: 103616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
    Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
    Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of levamisole on cytotoxic T-cell-mediated immune resistance to L1210 murine leukemia in hyperimmune mice.
    Gomi K; Morimoto M; Kataoka T
    Cancer Immunol Immunother; 1984; 17(3):195-9. PubMed ID: 6332672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
    Ujiie T
    Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of antitumor T-cells in tumor-bearing mice treated with tumor vaccine and 6-mercaptopurine.
    Kataoka T; Oh-hashi F
    Cancer Res; 1985 Jul; 45(7):2962-6. PubMed ID: 3873988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of Y-12, 141 on immune response of dd mice. Studies on anti-allergic agents, V. (author's transl)].
    Goto K; Hisadome M; Terasawa M; Kadobe Y; Abe C; Shiokawa Y
    Nihon Yakurigaku Zasshi; 1981 May; 77(5):459-67. PubMed ID: 7028582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.